



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/826,960	04/15/2004	Sheng-Ping Zhong	10527-447001 / 02-200	2208
26191	7590	06/13/2007	EXAMINER	
FISH & RICHARDSON P.C. PO BOX 1022 MINNEAPOLIS, MN 55440-1022			ROZANSKI, MICHAEL T	
		ART UNIT	PAPER NUMBER	
		3768		
		MAIL DATE		DELIVERY MODE
		06/13/2007		PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/826,960	ZHONG ET AL.	
	Examiner	Art Unit	
	Michael Rozanski	3768	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 09 May 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-53 is/are pending in the application.
 - 4a) Of the above claim(s) 49-53 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-48 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 30 July 2004 is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date <u>9/9/05, 7/26/04, 4/15/04</u>	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Election/Restrictions

1. Applicant's election without traverse of claims 1-48 in the reply filed on 5/9/07 is acknowledged. Claims 49-53 are non-elected.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

3. Claims 1-3, 5-9, 14-23, 25-32, and 34-47 rejected under 35 U.S.C. 102(e) as being anticipated by *Pacetti* (US 6,574,497).

Claims 1-3, 5-9, 14-23, 25-32, and 34-47: *Pacetti* discloses generating an MR image of a medical device, such as a guidewire, guide catheter, endovascular graft, biopsy needle, stent, or inflatable balloon catheter, and proximate body tissue, wherein the device has incorporated therein an imaging material comprising selected MRI detectable nuclei, such as hydrogen, phosphor, fluorine, or sodium nuclei (col. 2, lines 12-24; col. 6, lines 13-37; col. 6, line 65-col. 7, line 5; col. 9, lines 26-44). MRI images are taken including at least a portion of the medical device, which comprises a first image data, and including MRI detectable nuclei contained in the imaging material,

Art Unit: 3768

which comprises a second image data, and are combined and displayed (col. 7, lines 8-29; col. 8, lines 4-37).

The MRI scanner is able to transmit excitation pulses for two processes at either the same or different frequencies, a distinct magnetic field strength can be used for each process, and the processes can be performed at the same or different times (col. 7, line 30-col. 8, line 3). The imaging material is a liquid, such as an emulsion, and is encapsulated in a microsphere or into the wall of the microporous polymer material of the medical device containing structural material, which can be coated with fluorine-19 imaging material (col. 8, line 56-col. 9, line 25; col. 10, lines 21-35; col. 11, lines 24-39). The coating can comprise a network of polymer chains (col. 11, lines 40-49). Imaging material also comprises a spin ½ nucleus or at least two spin ½ nuclei that are magnetically equivalent (col. 3, lines 40-52). Furthermore, the device comprises a relaxation agent that decreases the spin-lattice relaxation time of the nuclei contained in the medical device (col. 2, lines 25-42).

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 4 and 10-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over *Pacetti* (US 6,574,497).

Claims 4 and 10-13: Pacetti disclose using selected MRI detectable nuclei such as hydrogen and sodium, but do not specifically disclose using phosphor or iodine nuclei. It would have been obvious to one with ordinary skill in the art at the time the invention was to have incorporated such nuclei in order to permit improved MR imaging of a selected medical device and proximate body tissue under different conditions.

6. Claim 33 is rejected under 35 U.S.C. 103(a) as being unpatentable over *Pacetti* in view of *Young et al* (US 5,817,017).

Claim 33: Pacetti substantially discloses all features of the current invention but does not specifically disclose microporous material comprising a film or a foam. In the same field of endeavor, Young et al teach such a film (col. 8, lines 40-59). It would have been obvious to one with ordinary skill in the art at the time the invention was made to have incorporated the teaching of Young et al in order to enable a liquid to be encapsulated therein.

7. Claim 48 is rejected under 35 U.S.C. 103(a) as being unpatentable over *Pacetti* in view of *Chui* (US Pub 2002/0101241).

Claim 48: Pacetti substantially discloses all features of the current invention but does not specifically disclose a receiver coil of a medical device. In the same field of endeavor, Chui teaches of a medical device with an RF internal receiving coil that is used to provide magnetic resonance imaging enhancement (see Abstract). It would

Art Unit: 3768

have been obvious to one with ordinary skill in the art at the time the invention was made to have incorporated the teaching of Chui in order to enhance MR imaging.

Conclusion

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Rozanski whose telephone number is 571-272-1648. The examiner can normally be reached on Monday - Friday, 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eleni Mantis-Mercader can be reached on 571-272-4740. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MR

MR

Eleni Mantis Mercader
ELENI MANTIS MERCADER
SUPERVISORY PATENT EXAMINER